what is the important rule to remember when administering delayed-release tablets and capsules

+ +

The pharmaceutical industry has been developing newer modified-release drug products at a very rapid step. Many of these modified-release drug products accept patented drug delivery systems. This chapter provides an overview of some of the more widely used methods for the manufacture of modified drug products.

+ +

The extended-release drug production is designed to comprise a drug dose which will release drug at a desired rate over a specified catamenia of fourth dimension. As discussed previously, the extended-release drug product may also incorporate an immediate-release component. The general approaches to manufacturing an extended-release drug production include the employ of a matrix structure in which the drug is suspended or dissolved, the utilize of a rate-controlling membrane through which the drug diffuses, or a combination of both. None of the extended-release drug products works by a single drug-release machinery. Most extended-release products release drug by a combination of processes involving drug dissolution, permeation, erosion, and diffusion. The single nigh important cistron is h2o permeation into the drug product, without which none of the production release mechanisms would operate. Controlling the charge per unit of h2o influx into the production more often than not dictates the charge per unit at which the drug dissolves in the gastrointestinal tract. Once the drug is dissolved, the rate of drug improvidence may be farther controlled to a desirable charge per unit. Tabular array 17-3 describes some common extended-release product examples and the mechanisms for controlling drug release. Table 17-4 lists the composition for some drugs.

+ +

Tabular array Graphic Jump Location

Table 17-three Examples of Oral Modified-Release Drug Products

View Table| |Download (.pdf)

Tabular array 17-3 Examples of Oral Modified-Release Drug Products

	Type	Trade Proper name	Rationale
Extended-Release Drug Products	Erosion tablet	Constant-T	Theophylline
		Tenuate Dospan	Diethylpropion HCl dispersed in hydrophilic matrix
		Tedral SA	Combination product with a slow-erosion component ( theophylline, ephedrine HCl) and an initial-release component theophylline, ephedrine HCl, phenobarbital)
	Waxy matrix tablet	Kaon CI	Slow release of potassium chloride to reduce GI irritation
	Coated pellets in sheathing	Ornade spansule	Combination phenylpropanolamine HCl and chlorpheniramine with initial-and extended-release component
	Pellets in tablet	Theo- Dur	Theophylline
	Leaching	Ferro-Gradumet (Abbott)	Ferrous sulfate in a porous plastic matrix that is excreted in the stool; slow release of iron decreases GI irritation
		Desoxyn gradumet tablet (Abbott)	Methamphetamine methylacrylate methylmethacrylate copolymer, povidone, magnesium stearate; the plastic matrix is porous
	Coated ion exchange	Tussionex	Cation ion-exchange resin complex of hydrocodone and phenyltoloxamine
	Flotation–diffusion	Valrelease	Diazapam
	Osmotic delivery	Acutrim	Phenylpropanolamine HCl (Oros delivery organization)
		Procardia-XL	GITS—Gastrointestinal therapeutic system with NaCl-driven (osmotic pressure level) delivery system for nifedipine
	Microencapsulation	Bayer timed-release	Aspirin
		Nitrospan	Microencapsulated nitroglycerin
		Micro-Grand Extencaps	Potassium chloride microencapsulated particles
Delayed-release drug products		diclofenac sodium enteric-coated tablets	Enteric blanket dissolves at pH >5 for release of drug in duodenum
		mesalamine) delayed-release tablets	Delayed-release tablets are coated with acrylic based resin, Eudragit Southward (methacrylic acid copolymer B, NF), which dissolves at pH 7 or greater, releasing mesalamine in the terminal ileum and beyond for topical anti-inflammatory action in the colon
Orally disintegrating tables

+ +

Table Graphic Jump Location

Table 17-iv Composition and Examples of Some Modified-Release Products

View Table| |Download (.pdf)

Table 17-4 Composition and Examples of Some Modified-Release Products

One thousand-Tab (Abbott)	750 mg or x mEq of potassium chloride in a film-coated matrix tablet. The matrix may be excreted intact, but the active ingredient is released slowly without upsetting the GI tract.
	Inert ingredients: Cellulosic polymers, castor oil, colloidal silicon dioxide, polyvinyl acetate, alkane. The product is listed as a waxy/polymer matrix tablet for release over viii–10 h.
Toprol-Forty tablets (Astra)	Contains metoprolol succinate for sustained release in pellets, providing stable beta-occludent over 24 h with one daily dose. Do tachycardia was less pronounced compared to immediate-release preparation. Each pellet separately releases the intended corporeality of medication.
	Inert ingredients: Paraffin, PEG, povidone, acetyltributyl citrate, starch, silicon dioxide, and magnesium stearate.
Quinglute Dura tablets (Berlex)	Contains 320 mg quinidine gluconate in a prolonged-activeness matrix tablet lasting 8–12 h and provides PVC protection.
	Inert ingredients: Starch, confectioner's sugar and magnesium stearate.
Brontil Tedious-Release capsules (Carnrick)	Phendimetrazine tartrate 105 mg sustained pellet in sheathing.
Ho-hum Fe tablets (Ciba)	Irksome-release iron preparation (OTC medication) with 160 mg ferrous sulfate for iron deficiency.
	Inert ingredients: HPMC, PEG shellac, and cetostearyl booze.
Tegretol-XR tablets (Ciba Geneva)	Carbamazepine extended-release tablet.
	Inert ingredients: Zein, cetostearyl alcohol, PEG, starch, talc, mucilage tragacanth, and mineral oil.
Sinemed CR tablets (Dupont pharma)	Contains a combination of carbidopa and levodopa for sustained-release delivery. This is a special erosion polymeric tablet for Parkinson's disease treatment.
Pentasa capsules (Hoechst Marion/Roussel)	Contains mesalamine for ulcerative colitis in a sustained-release mesalamine coated with ethylcellulose. For local issue mostly, nearly xx% captivated versus 80% otherwise.
Isoptin SR (Knoll)	Verapamil HCl sustained-release tablet.
	Inert ingredients: PEG, starch, PVP, alginate, talc, HPMC, methylcellulose, and microcrystalline cellulose.
Pancrease capsules (McNeil)	Enteric-coated microspheres of pancrelipase. Protects the amylase, lipase, and protease from the action of acid in the stomach.
	Inert ingredients: CAP, diethyl phthalate, sodium starch glycolate, starch, sugar, gelatin, and talc.
Cotazym-S (Organon)	Enteric-coated microspheres of pancrelipase.
Eryc ( erythromycin delayed-release capsules) (Warner-Chilcott)	Erythromycin enteric-coated tablet that protects the drug from instability and irritation.
Dilantin Kapseals (Parke-Davis)	Extended-release phenytoin capsule which contains beads of sodium phenytoin, gelatin, sodium lauryl sulfate, glyceryl monooleate, PEG 200, silicon dioxide, and talc.
Micro-K Extencaps (Robbins)	Ethylcellulose forms semipermeable film surrounding granules by microencapsulation for release over 8–x h without local irritation.
	Inert ingredients: Gelatin, and sodium lauryl sulfate.
Quinidex Extentabs (Robbins)	300-mg dose, 100-mg release immediately in the stomach and is absorbed in the small intestine. The residue is absorbed later over x–12 h in a irksome-dissolving core as it moves down the GI tract.
	Inert ingredients: White wax, carnauba wax, acacia, acetylated monoglyceride, guar gum, edible ink, calcium sulfate, corn derivative, and shellac.
Compazine Spansules (GSK)	Initial dose of prochlorperazine release starting time, then release slowly over several hours.
	Inert ingredients: Glycerylmonostearate, wax, gelatin, sodium lauryl sulfate.
Slo-bid Gyrocaps (Rhone-Poulenc Rorer)	A controlled-release 12–24-h theophylline product.
Theo-24 capsules (UCB Pharma)	A 24-hour sustained-release theophylline production.
	Inert ingredients: Ethylcellulose, edible ink, talc, starch, sucrose, gelatin, silicon dioxide, and dyes.
Sorbitrate SA (Zeneca)	The tablet contains isosorbide dinitrate x mg in the outer coat and 30 mg in the inner coat.
	Inert ingredients: Carbomer 934P, ethylcellulose, lactose magnesium stearate, and Yellow No. x.

+ + +

Drug Release from Matrix

+ +

A matrix is an inert solid vehicle in which a drug is uniformly suspended. A matrix may be formed by compressing or fusing the drug and the matrix textile together. Mostly, the drug is present in a pocket-size pct, so that the matrix protects the drug from rapid dissolution and the drug slowly diffuses out over time. Most matrix materials are water insoluble, although some matrix materials may swell slowly in h2o. Drug release using a matrix dosage course may be achieved using tablets or small beads, depending on the conception limerick and therapeutic objective. Figure 17-7 shows three common approaches past which matrix mechanisms are employed. In Fig. 17-7A, the drug is coated with a soluble blanket, then drug release relies solely on the regulation of drug release by the matrix material. If the matrix is porous, water penetration volition be rapid and the drug will diffuse out chop-chop. A less porous matrix may give a longer elapsing of release. Unfortunately, drug release from a simple matrix tablet is not zero order. The Higuchi equation describes the release rate of a matrix tablet:

+ +

+ +

where Q = amount of drug release per cm2 of surface at time t, Due south = solubility of drug in g/cm3 in the dissolution medium, A = content of drug in insoluble matrix, P = porosity of matrix, D = diffusion coefficient of drug, and λ = tortuosity factor.

+ +

+ +

Figure 17-7B represents a matrix enclosed by an insoluble membrane, then the drug release rate is regulated past the permeability of the membrane as well as the matrix. Fig. 17-7C represents a matrix tablet enclosed with a combined film. The film becomes porous after dissolution of the soluble office of the film. An example of this is the combined motion picture formed by ethylcellulose and methylcellulose. Close to zero-order release has been obtained with this blazon of release mechanism.

+ + +

Gum-Blazon Matrix Tablets

+ +

Some excipients take a remarkable power to neat in the presence of h2o and form a substance with a gel-like consistency. When this happens, the gel provides a natural barrier to drug diffusion from the tablet. Because the gel-like fabric is quite viscous and may not disperse for hours, this arroyo provides a means for maintaining the drug for hours until all the drug has been completely dissolved and diffused into the intestinal fluid. Gelatin is a common gelling material. However, gelatin dissolves rapidly after the gel is formed. Drug excipients such as methylcellulose, gum tragacanth, Veegum, and alginic acid form a viscous mass and provide a useful matrix for controlling drug release and dissolution. Drug formulations with these excipients provide extended drug release for hours.

+ + +

Polymeric Matrix Tablets

+ +

Various polymeric materials accept been used to prolong the charge per unit of drug release. The near important characteristic of this type of preparation is that the prolonged release may concluding for days or weeks rather than for a shorter duration (as with other techniques). An early example of an oral polymeric matrix tablet was Gradumet (Abbott Laboratories), which was marketed as an iron preparation. The not-biodegradable plastic matrix provides a rigid geometric surface for drug improvidence, then that a relatively constant rate of drug release is obtained. In the instance of the iron grooming, the matrix reduces the exposure of the irritating drug to the GI mucosal tissues. The matrix is normally expelled unchanged in the feces afterwards all the drug has leached out.

+ +

Polymeric matrix tablets for oral employ are more often than not quite prophylactic. However, for certain patients with reduced GI movement caused past disease, polymeric matrix tablets should exist avoided, considering accumulation or obstruction of the GI tract by matrix tablets has been reported. Every bit an oral sustained-release product, the matrix tablet has not been pop. In contrast, the utilise of the matrix tablet in implantation has been more than popular.

+ +

The use of biodegradable polymeric material for extended release has been the focus of more recent research. One such example is polylactic acid copolymer, which degrades to lactic acid and eliminates the problem of retrieval after implantation.

+ +

Other polymers for drug formulations include polyacrylate, methacrylate, polyester, ethylene—vinyl acetate copolymer (EVA), polyglycolide, polylactide, and silicone. Of these, the hydrophilic polymers, such as polylactic acid and polyglycolic acid, erode in water and release the drug gradually over fourth dimension. A hydrophobic polymer such as EVA releases the drug over a longer elapsing fourth dimension of weeks or months. The rate of release may exist controlled by blending ii polymers and increasing the proportion of the more hydrophilic polymer, thus increasing the rate of drug release. The addition of a low-molecular-weight polylactide to a polylactide polymer formulation increased the release rate of the drug and enabled the training of an extended-release system (Bodmeier et al, 1989). The type of plasticizer and the degree of cantankerous-linking provide additional ways for modifying the release rate of the drug. Many drugs are incorporated into the polymer every bit the polymer is formed chemically from its monomer. Low-cal, estrus, and other agents may affect the polymer chain length, degree of cross-linking, and other properties. This may provide a style to modify the release rate of the polymer matrices prepared. Drugs incorporated into polymers may take release rates that last over days, weeks, or even months. These vehicles have been often recommended for protein and peptide drug administration. For example, EVA is biocompatible and was shown to prolong insulin release in rats.

+ +

Hydrophobic polymers with h2o-labile linkages are prepared so that partial breakdown of the polymers allows for desired drug release without deforming the matrix during erosion. For oral drug delivery, the trouble of incomplete drug release from the matrix is a major hurdle that must be overcome with the polymeric matrix dosage form. Another problem is that drug release rates may be afflicted by the corporeality of drug loaded. For implantation and other uses, the environment is more stable compared to oral routes, and so a stable drug release from the polymer matrix may be attained for days or weeks.

+ + +

Irksome-Release Pellets, Beads or Granules

+ +

Pellets or beads are small spherical particles that can be formulated to provide a variety of modified drug release properties. The size of these beads can be very small (microencapsulation) for injections or larger for oral drug delivery. Several approaches have been used to manufacture beaded formulations incuding pan coating, spray drying, fluid bed drying, and extrusion-spheronization.

+ +

An early approach to the manufacture of ER drug products was the use of encapsulated drugs in a beaded or pellet formulation. In general, the beads are prepared by coating the powdered drug onto preformed cores known equally nonpareil seeds. The nonpareil seeds are made from a slurry of starch, sucrose, and lactose. The drug-coated chaplet are then coated by a diversity of materials that human action as a barrier to drug release. The chaplet may have a alloy of different thicknesses to provide the desired drug release. The beads may be placed in a capsule (eg, amphetamine ER capsules, Adderall XR) or with the addition of other excipients compressed into tablets (eg, metoprolol succinate extended-release tablets, Toprol XL).

+ +

Pan coating is a modified method adopted from candy manufacturing. Cores or nonpareil seeds of a given mesh size are slowly added to known amount of fine drug powder and blanket solution and rounded for hours to become coated drug beads. The drug-coated beads are so coated with a polymeric layer which regulates drug release rate past irresolute either the thickness of the motion-picture show or the limerick of the polymeric textile. Coatings may be aqueous or nonaqueous. Aqueous coatings are generally preferred. Nonaqueous coatings may get out residual solvents in the production, and the removal of solvents during manufacture presents danger to workers and the environment. Cores are coated by either sprayed pan coating or by air-break coating. One time the drug beads are prepared, they may be further coated with a protective coating to allow a sustained or prolonged release of the drug. Spray dry coating or fluid-bed blanket is a more than contempo approach and has several advantages over pan coating. Drug may be dissolved in a solution that is sprayed or dispersed in small-scale droplets in a bedchamber. A stream of hot air evaporates the solvent and the drug becomes a dry out powder. The powdered fabric which is aerated may be coated with a variety of excipients to achieve the desired drug release. Several experimental process variables for fluid-bed coating include inlet air temperature, spray rate (k/min), atomizing air pressure level, solid content, and curing fourth dimension. Pelletization may also exist obtained past extrusion-spheronization in which the powdered drug and excipients are mixed in a mixer/granulator. The moist mixture is then fed through an extruder at a specified charge per unit and becomes spheronized on go out though pocket-sized diameter dies. A wide range of extrusion screen sizes and configurations are available for optimization of pellet diameter.

+ +

The use of various amounts of coating solution can provide beads with diverse blanket protection. A careful blending of beads is used to reach a desired drug release profile. The finished drug production (eg, beads in capsule or beads in tablet) may contain a blend of beads coated with materials of different solubility rates to provide a ways of controlling drug release and dissolution.

+ +

Some products take advantage of bead blending to provide two doses of drug in one conception. For case, a blend of rapid-release chaplet with some pH-sensitive enteric-coated material may provide a second dose of drug release when the drug reaches the intestine.

+ +

The pellet dosage class can be prepared equally a capsule or tablet. When pellets are prepared every bit tablets, the beads must be compressed lightly so that they do not break. Usually, a disintegrant is included in the tablet, causing the beads to exist released rapidly afterwards administration. Conception of a drug into pellet form may reduce gastric irritation, considering the drug is released slowly over a period of time, therefore avoiding high drug concentration in the tummy. Dextroamphetamine sulfate formulated as timed-release pellets in capsules (Dexedrine Spansule) is an early instance of a beaded dosage form. Another older product is a pellet-type extended-release product of theophylline (Gyrocap). Table 17-5 shows the frequency of agin reactions afterward theophylline is administered as a solution or as pellets. If theophylline is administered as a solution, a high drug concentration is reached in the body due to rapid drug absorption. Some side effects may be attributed to the high concentration of theophylline. Pellet dosage forms allows drug to be absorbed gradually, therefore reducing the incidence of side furnishings by preventing a high C max.

+ +

Table Graphic Jump Location

Table 17-5 Incidence of Adverse Furnishings of Sustained-Release Theophylline Pellet versus Theophylline Solution a

View Tabular array| |Download (.pdf)

Table 17-5 Incidence of Agin Effects of Sustained-Release Theophylline Pellet versus Theophylline Solution a

	Volunteers Showing Side Effects
Side Effects	Using Solution	Using Sustained-Release Pellets
Nausea	10	0
Headache	4	0
Diarrhea	three	0
Gastritis	ii	0
Vertigo	5	0
Nervousness	3	i

a After 5-twenty-four hours dosing at 600 mg theophylline/24 h, adverse reaction points on fifth twenty-four hours: solution, 135; pellets, 18.

From Breimer and Dauhof (1980), with permission.

+ +

Bitolterol mesylate (Tornalate) is a β 2-adrenergic receptor agonist used equally a bronchodilator in asthma. A written report in dogs indicated that the incidence of tachycardia was reduced using an extended-release bead preparation, whereas the bronchodilation effect was not reduced. Administering the drug equally extended-release pellets patently reduced excessively high drug concentration in the body and avoided stimulating an increase in heart charge per unit. Studies also reported reduced gastrointestinal side effects of the drug potassium chloride in pellet or microparticulate form. Potassium chloride is irritating to the GI tract. Formulation of potassium chloride in pellet form reduces the chance of exposing high concentrations of potassium chloride to the mucosal cells in the GI tract.

+ +

Many extended-release cold products also use the bead formulation approach. A major reward of pellet dosage forms is that the pellets are less affected past tum elimination. Because numerous pellets are within a sheathing, some pellets will gradually accomplish the modest intestine each time the stomach empties, whereas a single extended-release tablet may exist delayed in the stomach for a long time as a effect of erratic tum emptying. Stomach elimination time is particularly important in the conception and in vivo behavior of enteric-coated products. Enteric-coated tablets may be delayed for hours by the presence of food in the stomach, whereas enteric-coated pellets are relatively unaffected by the presence of nutrient.

+ + +

Prolonged-Action Tablets

+ +

An alternate approach to prolong the action of a drug is to reduce the aqueous solubility of the drug, so that the drug dissolves slowly over a menstruation of several hours. The solubility of a drug is dependent on the salt form used. An exam of the solubility of the diverse salt forms of the drug is performed in early drug development. In general, the nonionized base or acid form of the drug is usually much less soluble than the corresponding salt. For example, sodium phenobarbital is more water soluble than phenobarbital, the acid form of the drug. Diphenhydramine hydrochloride is more soluble than the base form, diphenhydramine.

+ +

In cases where it is inconvenient to prepare a less soluble class of the drug, the drug may exist granulated with an excipient to slow dissolution of the drug. Oft, fatty or waxy lipophilic materials are employed in formulations. Stearic acrid, castor wax, high-molecular-weight polyethylene glycol (Carbowax), glyceryl monosterate, white wax, and spermaceti oil are useful ingredients in providing an oily bulwark to slow h2o penetration and the dissolution of the tablet. Many of the lubricants used in tableting may also be used every bit lipophilic agents to deadening dissolution. For instance, magnesium stearate and hydrogenated vegetable oil (Sterotex) are really used in high percentages to cause sustained drug release in a preparation. The major disadvantage of this type of preparation is the difficulty in maintaining a reproducible drug release from patient to patient, because oily materials may be subjected to digestion, temperature, and mechanical stress, which may bear on the release charge per unit of the drug.

+ + +

Ion-Commutation Products

+ +

Ion-exchange preparations usually involve an insoluble resin capable of reacting with either an anionic or cationic drug. An anionic resin is negatively charged and so that a positively charged cationic drug may react with the resin to course an insoluble nonabsorbable resin–drug complex. Upon exposure in the GI tract, cations in the gut, such as potassium and sodium, may displace the drug from the resin, releasing the drug, which is absorbed freely. The chief disadvantage of ion-exchange preparations is that the amount of cation–anion in the GI tract is not easily controllable and varies amongst individuals, making it hard to provide a consequent machinery or rate of drug release. A further disadvantage is that resins may provide a potential ways of interaction with nutrients and other drugs.

+ +

Ion exchange may be used in extended-release liquid preparations. An added advantage is that the technique provides some protection for very bitter or irritating drugs. Ion substitution has been combined with a coating to obtain a more effective sustained-release product. Examples include dextromethorphan polistirex (Delsyn®), an oral suspension formulated as an ion-exchange complex to mask the bitter gustation and to prolong the duration of drug activeness, and Tussionex Pennkinetic®, an oral suspension containing chlorpheniramine polistirex and hydrocodone polistirex.

+ +

A general mechanism for the conception of cationic drugs is

+ +

+ +

For anionic drugs, the respective mechanism is

+ +

+ +

The insoluble drug complex containing the resin and drug dissociates in the GI tract in the presence of the appropriate counter ions. The released drug dissolves in the fluids of the GI tract and is apace captivated.

+ +

A core tablet is a tablet inside a tablet. The inner core is commonly used for the slow-drug-release component, and the exterior shell contains a rapid-release dose of drug. Formulation of a core tablet requires two granulations. The core granulation is usually compressed lightly to course a loose core and and then transferred to a second die cavity, where a second granulation containing additional ingredients is compressed farther to form the concluding tablet.

+ +

The core cloth may be surrounded by hydrophobic excipients so that the drug leaches out over a prolonged menstruation of time. This type of preparation is sometimes called a slow-erosion core tablet, because the cadre by and large contains either no disintegrant or insufficient disintegrant to fragment the tablet. The composition of the core may range from wax to mucilage or polymeric material. Numerous slow-erosion tablets have been patented and are sold commercially under various merchandise names.

+ +

The success of core tablets depends very much on the nature of the drug and the excipients used. As a general rule, this preparation is very much hardness dependent in its release rate. Disquisitional command of hardness and processing variables are of import in producing a tablet with a consistent release charge per unit.

+ +

Cadre tablets are occasionally used to avoid incompatibility in preparations containing two physically incompatible ingredients. For example, buffered aspirin has been formulated into a cadre and shell to avoid a yellowing discoloration of the two ingredients upon aging.

+ +

Microencapsulation is a process of encapsulating microscopic drug particles with a special blanket material, therefore making the drug particles more desirable in terms of physical and chemical characteristics. A common drug that has been encapsulated is aspirin. Aspirin has been microencapsulated with ethylcellulose, making the drug superior in its flow characteristics; when compressed into a tablet, the drug releases more gradually compared to a simple compressed tablet.

+ +

Many techniques are used in microencapsulating a drug. One process used in microencapsulating acetaminophen involves suspending the drug in an aqueous solution while stirring. The coating material, ethylcellulose, is dissolved in cyclohexane, and the two liquids are added together with stirring and heating. As the cyclohexane is evaporated by rut, the ethylcellulose coats the microparticles of the acetaminophen. The microencapsulated particles take a slower dissolution rate considering the ethylcellulose is not water soluble and provides a barrier for diffusion of drug. The amount of coating textile deposited on the acetaminophen determines the rate of drug dissolution. The blanket also serves as a means of reducing the bitter taste of the drug. In practice, microencapsulation is not consequent enough to produce a reproducible batch of product, and it may be necessary to blend the microencapsulated material in club to obtain a desired release rate.

+ + +

Osmotic Drug Delivery Systems

+ +

Osmotic drug delivery systems have been adult for both oral extended-release products known as gastrointestinal therapeutic systems (GITS) and for parenteral drug delivery as an implantable drug delivery (eg, osmotic minipump). Drug delivery is controlled past the use of an osmotically controlled device in which a abiding amount of water flows into the system causing the dissolving and releasing of a abiding corporeality of drug per unit time. Drug is released via a single laser-drilled pigsty in the tablet.

+ +

Figure 17-8 describes an osmotic drug commitment organization in the class of a tablet which contains an outside semipermeable membrane and an inner core filled with a mixture of drug and osmotic agent (common salt solution). When the tablet is placed in h2o, osmotic pressure is generated by the osmotic agent within the cadre. Water moves into the device, forcing the dissolved drug to exit the tablet through an orifice. The rate of drug delivery is relatively constant and unaffected by the pH of the environs.

+ +

Figure 17-8

Graphic Bound Location

Cross section of the extended-release hydromorphone tablet.

(Adapted with permission from Gupta South, Sathyan Thousand. Providing constant analgesia with OROS® hydromorphone. J Pain Symptom Manage. 2007;33(2 suppl): S19-S24.)

+ +

Newer osmotic drug commitment systems are considered "button-pull" systems. Nifedine (Procardia Xl) extended-release tablets have the appearance of a conventional tablet. Procardia XL ER tablets have a semipermeable membrane surrounding an osmotically active drug core. The core itself is divided into two layers: an "active" layer containing the drug, and a "push" layer containing pharmacologically inert (merely osmotically agile) components. As water from the gastrointestinal tract enters the tablet, pressure increases in the osmotic layer and "pushes" against the drug layer, releasing drug through a laser-drilled tablet orifice in the active layer. Drug delivery is essentially abiding (zero club) every bit long as the osmotic gradient remains constant, then gradually falls to zero. Upon swallowing, the biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the feces as an insoluble shell.

+ +

Methylphenidate HCl (Concerta®) extended- release tablets uses osmotic force per unit area to deliver methylphenidate HCl at a controlled rate. The arrangement, which resembles a conventional tablet in advent, comprises an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat. The trilayer core is composed of ii drug layers containing the drug and excipients, and a push layer containing osmotically agile components. A laser-drilled orifice on the drug-layer end of the tablet allows for exit of the drug. This production is similar to the GITS discussed before. The biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the stool as an insoluble tablet beat.

+ +

The frequency of side effects experienced by patients using GITS was considerably less than that with conventional tablets. When the therapeutic system was compared to the regular 250-mg tablet given twice daily, ocular pressure level was effectively controlled by the osmotic organisation. The claret level of acetazolanine using GITS, however, was considerably below that from the tablet. In fact, the therapeutic alphabetize of the drug was measurably increased by using the therapeutic organisation. The use of extended-release drug products, which release drug consistently, may provide hope for administering many drugs that previously had frequent adverse side furnishings because of the drug's narrow therapeutic index. The osmotic drug delivery system has become a popular drug vehicle for many products that crave an extended period of drug delivery for 12 to 24 hours (Table 17-6).

+ +

Table Graphic Jump Location

Table 17-vi OROS Osmotic Therapeutic Systems a

View Table| |Download (.pdf)

Table 17-half-dozen OROS Osmotic Therapeutic Systems a

Trade Name	Manufacturer	Generic Name	Description
Acutrim	Ciba	Phenylpropanolamine	In one case-daily, over-the-counter appetite suppressant
Covera-HS	Searle	Verapamil	Controlled-Onset Extended-Release (COER-24) organisation for hypertension and angina pectoris
DynaCirc CR	Sandoz Pharmaceuticals	Isradipine	Treatment of hypertension
Efidac 24	Ciba Self-Medication		Over-the-counter, 24-hour extended-release tablets providing relief of allergy and cold symptoms, containing either chlorpheniramine maleate, pseudoephedrine hydrochloride, or a combination of pseudoephedrine hydrochloride/ brompheniramine maleate
Glucotrol XL	Pfizer	Glipizide	Extended-release tablets indicated as an adjunct to nutrition for the control of hyperglycemia in patients with non-insulin-dependent diabetes
Minipress Xl	Pfizer	Prazosin	Extended-release tablets for handling of hypertension
Procardia Twoscore	Pfizer	Nifedipine	Extended-release tablets for treatment of angina and hypertension
Adalat CR	Bayer AG	Nifedipine	An Alza-based OROS system of nifedipine introduced internationally
Volmax	Glaxo-Wellcome	Albuterol	Extended-release tablets for the relief of bronchospasm in patients with reversible obstructive airway affliction

a Alza's OROS Osmotic Therapeutic Systems utilize osmosis to deliver drug continuosly at controlled rates for upwards to 24 h.

+ +

A newer osmotic commitment system is the L-Oros Softcap (Alza), which claims to enhance bioavailability of poorly soluble drug by formulating the drug in a soft gelatin cadre and so providing extended drug delivery through an orifice drilled into an osmotic driven vanquish (Fig. 17-9). The soft gelatin capsule is surrounded by the bulwark layer, the expanding osmotic layer, and the release-rate-controlling membrane. A delivery orifice is formed through the three outer layers but non through the gelatin beat out. When the arrangement is administered, h2o permeates through the rate-controlling membrane and activates the osmotic engine. Every bit the engine expands, hydrostatic pressure inside the system builds up, thereby forcing the liquid conception to break through the hydrated gelatin capsule trounce at the delivery orifice and be pumped out of the system. At the end of the performance, liquid drug fill is squeezed out, and the gelatin capsule beat becomes flattened. The osmotic layer, located between the inner layer and the rate-controlling membrane, is the driving force for pumping the liquid formulation out of the system. This layer can gel when it hydrates. In addition, the high osmotic pressure can be sustained to reach a abiding release. This layer should comprise, therefore, a high-molecular-weight hydrophilic polymer and an osmotic agent. Information technology is a challenge to develop a coating solution for a high-molecular-weight hydrophilic polymer. A mixed solvent of water and ethanol was used for this blanket composition.

+ +

Figure 17-9

Graphic Jump Location

Configuration of L-Oros Softcap.

(From Dong et al, 2002, with permission.)

+ + +

Gastroretentive Organisation

+ +

The extended-release drug product should release the drug completely within the region in the GI tract in which the drug is optimally absorbed. Due to GI transit, the extended-release drug production continuously moves distally down the GI tract. In some cases, the extended-release drug production containing residual drug may exit from the body. Pharmaceutical formulation developers have used various approaches to retain the dosage class in the desired surface area of the alimentary canal. I such approach is a gastroretentive system that can remain in the gastric region for several hours and prolong the gastric residence fourth dimension of drugs (Arora et al, 2005). These gastroretentive systems are sometimes referred to as floating drug commitment systems. For example, diazepam (Valium) was been formulated using methylcellulose to provide sustained release (Valrelease). The manufacturer of Valrelease claimed that the hydrocolloid (gel) floated in the breadbasket to give sustained release diazepam. In other studies, nevertheless, materials of various densities were emptied from the breadbasket without whatsoever departure as to whether the drug product was floating on top or sitting at the bottom of the stomach.

+ +

The most important consideration in this blazon of conception appears to exist the gelling strength of the gum textile and the concentration of gummy material. Modification of the release rates of the product may further be achieved with various amounts of talc or other lipophilic lubricant.

+ + +

Transdermal Drug Commitment Systems

+ +

A transdermal drug delivery system (patch) is a dosage grade intended for delivering drug across the skin for systemic drug absorption (run across Chapters 7, xiii). Transdermal drug assimilation also avoids presystemic metabolism or "kickoff-pass" effects. The transdermal drug commitment systems evangelize the drug through the peel in a controlled charge per unit over an extended menstruation of fourth dimension (Chapter 14, Table fourteen-12). Examples of transdermal drug commitment systems are listed in Tables 17-7 and 17-8. Transdermal delivery drug products vary in patch blueprint (Fig. 17-10). Generally, the transdermal patch consists of (i) a backing or back up layer that protects the patch, (two) a drug layer that might be in the class of a solid gel reservoir or in a matrix, (three) a pressure level-sensitive adhesive layer, and (4) a release liner or protective strip that is removed before placing the patch on the skin. In some cases, the agglutinative layer may likewise contain the active drug (Gonzalez and Cleary, 2010).

+ +

Table Graphic Bound Location

Table 17-7 Examples of Transdermal Commitment Systems

View Tabular array| |Download (.pdf)

Table 17-vii Examples of Transdermal Delivery Systems

Type	Trade Name	Rationale
Membrane-controlled system	Transderm-Nitro (Novartis)	Drug in reservoir, drug release through a charge per unit-controlling polymeric membrane
Agglutinative improvidence-controlled system	Deponit organisation (PharmaSchwartz)	Drug dispersed in an agglutinative polymer and in a reservoir
Matrix-dispersion system	Nitro- Dur (Fundamental)	Drug dispersed into a rate-controlling hydrophilic or hydrophobic matrix molded into a transdermal arrangement
Microreservoir organization	Nitro-Disc (Searle)	Combination reservoir and matrix-dispersion system

+ +

Table Graphic Spring Location

Tabular array 17-8 Transdermal Delivery Systems

View Tabular array| |Download (.pdf)

Table 17-8 Transdermal Commitment Systems

Merchandise Name	Manufacturer	Generic Name	Description
Catapres-TTS	Boehringer Ingelheim	Clonidine	Once-weekly production for the handling of hypertension
Duragesic	Janssen Pharmaceutical	Fentanyl	Direction of chronic hurting in patients who crave continuous opioid analgesia for pain that cannot be managed by lesser means
Estraderm	Ciba-Geigy	Estradiol	Twice-weekly product for treating sure postmenopausal symptoms and preventing osteoporosis
Nicoderm CQ	Hoechst Marion	Nicotine	An aid to smoking cessation for the relief of nicotine-withdrawal symptoms
Testoderm	Alza	Testosterone	Replacement therapy in males for conditions associated with a deficiency or absenteeism of endogenous testosterone
Transderm-Nitro	Novartis	Nitroglycerin	In one case-daily production for the prevention of angina pectoris due to coronary artery disease; contains nitroglycerin in a proprietary, transdermal therapeutic system
Transderm Scop		Scopolamine	Prevention of nausea and vomiting associated with motion sickness

+ +

+ +

Drug diffusion may exist controlled by a semipermeable membrane next to the reservoir layer. In other cases, drug diffusion is controlled by passage through the epidermis layer of the skin. The transdermal delivery system generally contains large drug concentrations to produce the ideal drug commitment with a zero-order rate. The patch may comprise remainder drug when the patch is removed from the application site.

+ +

Nitroglycerin is unremarkably administered by transdermal delivery (eg, Nitro- Dur, Transderm-Nitro®). Transdermal delivery systems of nitroglycerin may provide hours of protection against angina, whereas the elapsing of nitroglycerin given in a sublingual tablet (Nitrostat®) or sublingual spray (Nitrolingual) may be simply a few minutes. The nitroglycerin patch is placed over the chest expanse and provides up to 12 hours of angina protection. In a study comparing these three dosage forms in patients, no substantial difference was observed amid the 3 preparations. In all cases, the peel was found to be the charge per unit-limiting stride in nitroglycerin absorption. In that location were fewer variations among products than of the aforementioned product among different patients.

+ +

The skin is a natural barrier to preclude the influx of strange chemicals (including h2o) into the body and the loss of water from the body (Guy, 1996). To be a suitable candidate for transdermal drug commitment, the drug must possess the right combination of physicochemical and pharmacodynamic properties. The drug must be highly potent and so that only a small systemic drug dose is needed and the size of the patch (dose is also related to surface expanse) need not be uncommonly large, non greater than 50 cm2 (Guy, 1996). Physicochemical properties of the drug include a pocket-sized molecular weight (<500 Da), and high lipid solubility. The elimination half-life should not be too short, to avoid having to utilise the patch more than frequently than one time a day.

+ +

Afterward the awarding of a transdermal patch, there is generally a lag time before the onset of the drug action, because of the drug's slow diffusion into the dermal layers of the skin. When the patch is removed, diffusion of the drug from the dermal layer to the systemic apportionment may go on for some time until the drug is depleted from the site of application. The solubility of drug in the skin rather than the concentration of drug in the patch layer is the most important factor controlling the rate of drug absorption through the skin. Humidity, temperature, and other factors have been shown to bear upon the rate of drug absorption through the skin. With most drugs, transdermal commitment provides a more than stable blood level of the drug than oral dosing. Notwithstanding, with nitroglycerin, the sustained blood level of the drug provided past transdermal delivery is not desirable, due to induced tolerance to the drug not seen with sublingual tablets.

+ +

Transdermal Therapeutic Systems (TTS) consist of a sparse, flexible composite of membranes, resembling a small adhesive bandage, which is applied to the skin and delivers drug through intact skin into the bloodstream. Other examples of products delivered using this organization are shown in Tabular array 17-8. Transderm Nitro consists of several layers: (1) an aluminized plastic backing that protects nitroglycerin from loss through vaporization; (2) a drug reservoir containing nitroglycerin adsorbed onto lactose, colloidal silicon dioxide, and silicone medical fluid; (three) a improvidence-decision-making membrane consisting of ethylene–vinyl acetate copolymer; (4) a layer of silicone adhesive; and (5) a protective strip.

+ +

Other transdermal delivery manufacturers have fabricated transdermal systems in which the agglutinative functions both as a pressure-sensitive adhesive and every bit a controlling matrix. Dermaflex (Elan) is a uniquely passive transdermal patch organisation that employs a hydrogel matrix into which the drug is incorporated. Dermaflex regulates both the availability and absorption of the drug in a manner that allows for controlled and efficient systemic delivery of many drugs.

+ +

An important limitation of transdermal grooming is the corporeality of drug that is needed in the transdermal patch to be captivated systemically to provide the optimum therapeutic response. The amount of drug absorbed transdermally is related to the corporeality of drug in the patch, the size of the patch, and the method of manufacture. A dose–response relationship is obtained by applying a proportionally larger transdermal patch that differs merely in surface area. For case, a five-cmtwo transdermal patch volition by and large provide twice as much drug absorbed systemically every bit a 2.5-cm2 transdermal patch.

+ +

In general, drugs given at a dose of over 100 mg would crave likewise large a patch to be used practically. Withal, new advances in pharmaceutic solvents may provide a mechanism for an increased amount of drug to be absorbed transdermally. Azone, a permeation enhancer, is a solvent that increases the assimilation of many drugs through the pare. This solvent is relatively nontoxic.

+ +

For ionic drugs, absorption may be enhanced transdermally by iontophoresis, a method in which an electric field is maintained across the epidermal layer with special miniature electrodes. Some drugs, such as lidocaine, verapamil, insulin, and peptides, take been absorbed through the skin by iontophoresis. A process in which transdermal drug delivery is aided by loftier-frequency sound is called sonophoresis. Sonophoresis has been used with hydrocortisone cream applied to the skin to heighten penetration for treating "lawn tennis elbow" and other mild inflammatory muscular problems. Many such novel systems are being developed by drug commitment companies.

+ +

Panoderm XL patch technology (Elan) is a new system that delivers a drug through a concealed miniature probe which penetrates the stratum corneum. Panoderm Forty is fully disposable and may be programmed to evangelize drugs as a preset bolus, in continuous or pulsed regimen. The complexity of the device is hidden from the patient and is uncomplicated to apply. Panoderm (Elan) is an electrotransdermal drug delivery system that overcomes the pare diffusion barriers through the apply of low-level electric current to ship the drug through the pare. Several transdermal products, such equally fentanyl, hydromorphone, calcitonin, and LHRH (luteinizing hormone–releasing hormone), are in clinical trials. More improvements in transdermal delivery of larger molecules and the use of absorption enhancers will be available in future transdermal delivery systems.

+ +

Several boosted studies that are unique to the development of a transdermal drug delivery arrangement include: (ane) wearable and adhesiveness of the patch, (2) skin irritation, (3) pare sensitization, and (four) remainder drug in the patch after removal. The FDA is asking drug companies to consider minimizing the amount of remainder drug left in transdermal patches. Marketed products that use transdermal and transmucosal drug commitment systems tin incorporate between 10 percent and 95 percent of the initial active drug even afterward use, according to the FDA's draft guidance published in the Federal Register, Baronial 3, 2010. Adverse events accept been reported later patients have failed to remove a patch, resulting in increased or prolonged furnishings of the drug (eg, fentanyl patch).

+ +

Combination products are defined in 21 CFR 3.2(due east).2 The term combination product includes:

+ +

1. A product comprised of two or more regulated components, ie, drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity;

2. Two or more than split up products packaged together in a single packet or as a unit and comprised of drug and device products, device and biological products, or biological and drug products;

3. A drug, device, or biological production packaged separately that co-ordinate to its investigational plan or proposed labeling is intended for use only with an canonical individually specified drug, device, or biological product where both are required to achieve the intended utilize, indication, or event and where upon approval of the proposed production the labeling of the approved product would demand to be changed, eg, to reverberate a change in intended use, dosage form, strength, route of administration, or significant change in dose; or

4. Any investigational drug, device, or biological production packaged separately that according to its proposed labeling is for utilize but with some other individually specified investigational drug, device, or biological product where both are required to achieve the intended utilise, indication, or effect.

+ +

Examples of combination products where the components are physically, chemically, or otherwise combined:

+ +

• Monoclonal antibody combined with a therapeutic drug
• Device coated or impregnated with a drug or biologic
  • Drug-eluting stent; pacing pb with steroid-coated tip; catheter with antimicrobial coating; condom with spermicide
  • Skin substitutes with cellular components; orthopedic implant with growth factors
• Prefilled syringes, insulin injector pens, metered dose inhalers, transdermal patches
• Drug or biological product packaged with a delivery device
• Surgical tray with surgical instruments, drapes, and lidocaine or alcohol swabs
• Photosensitizing drug and activating light amplification by stimulated emission of radiation/light source
• Iontophoretic drug delivery patch and controller

+ +

In summary, combination products consist of the drug in combination with a device that is physically, chemically, or otherwise combined or mixed and produced as a single entity. The device and/or biologic is intended for employ with the approved drug and influences the route of assistants and pharmacokinetics of the drug.

+ + +

Modified-Release Parenteral Dosage Forms

+ +

Modified-release parenteral dosage forms are parenteral dosage forms that maintain plasma drug concentrations through charge per unit-controlled drug release from the formulation over a prolonged period of time (Patil and Burgess, 2010; Martinez, 2008). Some examples of modified-release parenteral dosage forms include microspheres, liposomes, drug implants, inserts, drug-eluting stents, and nanoparticles. These formulations are designed by entrapment or microencapsulation of the drug into inert polymeric or lipophilic matrices that slowly release the drug, in vivo, for the duration of several days or up to several years. Modified-release parenteral dosage forms may exist biodegradable or nonbiodegradable. Nonbiodegradable implants demand to be surgically removed at the end of therapy.

+ +

Polymeric drug implants tin can deliver and sustain drug levels in the trunk for an extended flow of time. Both biodegradable and nonbiodegradable polymers can be impregnated with drugs in a controlled drug delivery system. For example, levo-norgestrel implants (Norplant system, Wyeth-Ayerst) is a set of six flexible closed capsules made of silastic (dimethylsiloxane/methylvinylsiloxane copolymer), each containing 36 μchiliad of the progestin  levonorgestrel. The capsules are sealed with silastic agglutinative and sterilized. The Norplant system is available in an insertion kit to facilitate subdermal insertion of all six capsules in the mid-portion of the upper arm. The dose of levonorgestrel is nigh 85 μg/day, followed by a reject to about l μ1000/day past 9 months and to about 35 μg/day by 18 months, declining farther to about 30 μg/twenty-four hours (Facts and Comparisons, 1997). The levonorgestrel implants are constructive for up to five years for contraception so must be replaced. An intrauterine progesterone  contraceptive system (Progestasert, Alza) is a T-shaped unit that contains a reservoir of 38 μg of progesterone. Contraceptive effectiveness for Progestasert is enhanced past continuous release of progesterone into the uterine cavity at an average rate of 65 μg/day for 1 year.

+ +

A dental insert bachelor for the treatment of peridontitis is the doxycycline hyclate delivery system (Atrigel®). This is a subgingival controlled-release product consisting of two syringe mixing systems that, when combined, form a bioabsorbable, flowable polymeric formulation. After administration under the gum, the liquid solidifies and and then allows for controlled release of doxycycline for a menses of 7 days.

+ + +

Nanotechnology Derived Drugs

+ +

Nanotechnology is the industry of materials in the nanometer size range. Nanotechnology has been practical to drug development, food, electronics, biomaterials, and other applications. Nanoscale materials often accept chemical, physical, or biological properties that are dissimilar from those of their larger counterparts. Such differences may include altered magnetic properties, altered electrical or optical activity, increased structural integrity, or altered chemical or biological activity (Nanotechnology, FDA 2007). Because of these properties, nanoscale materials have great potential for apply in a variety of therapeutic agents. Because of some of their special properties, nanoscale materials may pose different safety and efficacy issues compared to their larger or smaller (ie, molecular) counterparts.

+ +

In improver to the large surface area of nanoparticles, surface area modification of the nanoparticles such as bounden different chemic groups to the surface with surfactants or biocompatible polymers (eg, polyethylene glycol, PEG) changes the pharmacokinetics, toxicity, and surface reactivity of the nanoparticles, in vivo. Therefore, nanoparticles can take a wide diversity of properties that are markedly different from the same materials in larger particle forms (Couvreur and Vauthier, 2006; run into likewise Affiliate 18).

+ +

A liposome is a microvesicle composed of a bilayer of lipid amphipathic molecules enclosing an aqueous compartment ( FDA Guidance, 2002). Liposomes may be nanoparticle size or larger. Liposome drug products are formed when a liposome is used to encapsulate a drug substance inside the lipid bilayer or in the interior aqueous space of the liposome depending on the physicochemical characteristics of the drug. Liposomes can exist composed of naturally-derived phospholipids with mixed lipid chains (like egg phosphatidylethanolamine) or other surfactants. Liposome drug products exhibit a dissimilar pharmacokinetic and/or tissue distribution contour from the same drug substance (or active moiety) in a non-liposomal formulation given by the same route of administration.

+ +

Daunorubicin has been used for the handling of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. Two different liposomal formulations of daunorubicin are currently marketed. DaunoXome® contains an aqueous solution of the citrate salt of daunorubicin encapsulated inside lipid vesicles ( liposomes) composed of a lipid bilayer of distearoylphosphatidylcholine and cholesterol, whereas Doxil® is doxorubicin HCl encapsulated in liposomes that are formulated with surface-bound methoxypolyethylene glycol (MPEG). The apply of MPEG is a process often referred to every bit pegylation, to protect liposomes from detection by the mononuclear phagocyte organisation (MPS) and to increment blood circulation time. Each of these products has different pharmacokinetics and they are not interchangeable.

+ +

| Print

Frequently Asked Questions

• How do patient-specific variables influence performance of modified-release dosage forms?
• What is the difference between the different types of modified-release dosage forms?

+ +

corbouldeaspost.blogspot.com

Source: https://accesspharmacy.mhmedical.com/content.aspx?bookid=513§ionid=41488035

Share this post